A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

This study of vosaroxin evaluated dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics (PK), clinical activity and pharmacodynamics in relapsed/refractory leukemia. Dosing was weekly (days 1, 8 and 15) or twice weekly (days 1, 4, 8 and 11). Seventy-three treated patients had...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Lancet, JE, Ravandi, F, Ricklis, RM, Cripe, LD, Kantarjian, HM, Giles, FJ, List, AF, Chen, T, Allen, RS, Fox, JA, Michelson, GC, Karp, JE
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4576993/
https://ncbi.nlm.nih.gov/pubmed/21760592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.157
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars